Haemodialysis

Haemodialysis is an extracorporeal procedure to remove waste products from the blood, such as creatinine and urea, which are insufficiently removed by the kidneys in patients with renal failure. During the procedure, patients’ blood is withdrawn and cleansed by filtration through a series of membranes before being returned to the patient.

Latest Research and Reviews

News and Comment

  • Comments & Opinion |

    Venezuela is going through a humanitarian crisis that has severely impacted all programmes of kidney replacement therapy — dialysis coverage has decreased markedly, particularly in small towns and rural areas, and almost all peritoneal dialysis and deceased donor organ procurement for kidney transplantation have been discontinued.

    • Ezequiel Bellorin-Font
    •  & Raul G. Carlini
  • Comments & Opinion |

    Insomnia is common among patients on maintenance haemodialysis and may be exacerbated by the challenges of the COVID pandemic. However, data on the efficacy of insomnia interventions in this population are limited. Efforts are needed to address this important problem and increase access to insomnia interventions for patients on haemodialysis.

    • Daniel Cukor
    • , Mark Unruh
    •  & Rajnish Mehrotra
  • News & Views |

    A new study reports the seroprevalence of SARS-CoV-2 antibodies among a cross-section of patients on haemodialysis and uses these data to estimate seroprevalence in the general US population. Although this study demonstrates the potential of monitoring infectious disease prevalence in dialysis populations, the findings should be interpreted with caution.

    • Viyaasan Mahalingasivam
    •  & Laurie Tomlinson
  • Comments & Opinion |

    Health-care professionals in general and nephrologists in particular can and should make clear contributions towards achieving the Sustainable Development Goals. This commitment will require changes in patient care, research and education, which should be carried out in collaboration with relevant stakeholders, such as health-care industries.

    • Peter J. Blankestijn
  • News & Views |

    Timing of dialysis initiation in critically ill patients is controversial. The STARRT-AKI trial reports that an accelerated initiation strategy did not improve 90-day survival and increased dialysis dependency compared with a standard approach in which patients had greater fluid accumulation and metabolic complications at initiation but 38% avoided dialysis.

    • Josée Bouchard
    •  & Ravindra Mehta
  • Comments & Opinion |

    Interest in the use of haemoperfusion for severe COVID-19 has been spurred by anecdotal reports of its efficacy and expert reviews suggesting theoretical benefits. However, on the basis of the limited current evidence, haemoperfusion remains an experimental therapy that should only be applied within the context of well-designed randomized trials.

    • Edward G. Clark
    • , Swapnil Hiremath
    •  & Michael Joannidis